LCZ-Mont Suspension is a combination pharmaceutical formulation containing Levocetirizine 5 mg and Montelukast 10 mg, designed for the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 histamine receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene D4 receptor, reducing bronchoconstriction, inflammation, and edema in the airways, making it effective in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief by targeting multiple pathways involved in allergic responses. LCZ-Mont Suspension is indicated for pediatric and adult patients requiring combined antihistaminic and leukotriene receptor antagonist therapy, particularly in cases where monotherapy is insufficient. The suspension formulation ensures ease of administration and dose flexibility. It is generally well-tolerated; however, clinicians should monitor for potential adverse effects such as headache, somnolence, gastrointestinal disturbances, and rare neuropsychiatric events. LCZ-Mont Suspension should be used under medical supervision with appropriate dosage adjustments based on patient response and tolerability.